Company / Cash & Equivalents
Phio Pharmaceuticals Corp. Cash & Equivalents History
FY2012-FY2017 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$3.6M
FY2017
5-year range
$3.6M / $12.9M
FY2013-FY2017
Trend
-72.3%
vs FY2016
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $5M to $4M over the past 4 years.
Based on SEC 10-K filings.
$4M in FY2017 with a 5-year CAGR of +48.1%.
Declined from $5M to $4M over the past 4 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- +48.1%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +48.1%, indicating consistent growth.
- In FY2017, cash & equivalents decreased 72.3% year-over-year.
Company context
Key Data Points
- Altman Z-Score -0.94 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | $3.6M | -72.3% |
| FY2016 | $12.9M | +151.7% |
| FY2013 | $5.1M | +919.3% |
| FY2012 | $503.0K | - |
As of FY2017 · SEC 10-K · Updated Jun 28, 2026